U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07275853) titled 'Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors' on Nov. 27.
Brief Summary: This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: KXV01 TCR Lentinvivo Injection
KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-rea...